Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

MIGS

MIGS
2013 FOUNDED
M&A STATUS
11-20 EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of antibody production and analysis platform. The company provides contract research services specializing in humanization and the production of antibody and antibody-like molecules that support preclinical studies with micro-gram to gram quantities of protein.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
ATUM
Primary Office
  • 16 Cavendish Court
  • Suite 227
  • Lebanon, NH 03766
  • United States

+1 (603) 000-0000

MIGS Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore MIGS‘s full profile, request access.

Request full access to PitchBook

MIGS Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DNA Script Venture Capital-Backed Paris, France 000.00 00000000000 000.00
0000 000 0000000 Private Equity-Backed Worcester, MA 00 00000 000000000000 00000
000000000 00000000 Venture Capital-Backed San Diego, CA 0 000.00 00000000000 000.00
0000000000 Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
00000 0000000000 Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
To view this company’s complete list of competitors, request access »

MIGS Executive Team (2)

Name Title Board
Seat
Contact
Info
Michael Feldhaus Ph.D Co-Founder & Chief Executive Officer
Jose Varghese Co-Founder & Advisor

MIGS Board Members (1)

Name Representing Role Since Contact
Info
00000 00000 00.0 MIGS Co-Founder, Board Member & Scientific Advisor 000 0000